

Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force

Torbjörn Tomson¹, Dina Battino², Rebecca Bromley³, Silvia Kochen⁴, Kimford J. Meador⁵,
Page B. Pennell⁶, Sanjeev V. Thomas⁷

¹ Department of Clinical Neuroscience Karolinska Institutet, Stockholm, Sweden

² Fondazione I.R.C.C.S. Istituto Neurologico CARLO BESTA, Milan, Italy

³ Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK; Royal Manchester Children's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK

⁴ Epilepsy Center, ENyS, CONICET, Hosp. El Cruce, Hosp. R. Mejía, Univ Buenos Aires, Argentina

⁵ Department of Neurology & Neurological Sciences, Stanford University, Palo Alto, CA, USA

⁶ Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

⁷ Department of Neurology, Institute for Communicative and Cognitive neurosciences, Trivandrum, Kerala State, India

Summary of data on levels of antiseizure medications in breastfed infants

1-2 Cases	3-10 mother/child pairs	>10 mother/child pairs	Extensive data
Brivaracetam	Gabapentin	Ethosuximide	Carbamazepine
Clonazepam	Oxcarbazepine	Phenobarbital	Lamotrigine
Lacosamide	Pregabalin	Phenytoin	Levetiracetam
Perampanel	Primidone	Topiramate	Valproate
	Zonisamide		

High infant levels (30%-100% of maternal levels) have occasionally been reported
Indicates availability of reassuring data on long-term neurodevelopment

Antiseizure medications (ASMs) for which data on levels in infants breastfed by mothers on treatment are lacking

ASM
Cannabidiol
Cenobamate
Clobazam
Eslicarbazepine
Evrolimus
Felbamate
Fenfluramine
Retigabine
Rufinamide
Stiripentol
Tiagabine
Vigabatrin